The Need in Diabetic Kidney Disease

September 10, 2015 Guest Contributor

James ListGuest post by James F. List, MD, PhD, Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen Research & Development LLC

According to the International Diabetes Federation, 387 million people worldwide are living with Type 2 diabetes mellitus (T2DM), and that number is expected to grow to 592 million by 2035.

This staggering global incidence has the Cardiovascular and Metabolism team at Janssen Research & Development (Janssen) working tirelessly to develop new ways to treat and ultimately eliminate diabetes and its complications by targeting underlying disease mechanisms, important pathways and novel mechanisms of action.

There are many devastating effects of diabetes. One of the most common is the damage it can do to your kidneys.  Nearly one-third of patients with T2DM will develop diabetic kidney disease (DKD), which is associated with an 8 percent per year mortality rate. Effectively, DKD is the most common cause of chronic kidney disease and end-stage renal disease worldwide.

The prevention and delayed progression of DKD is critical to the treatment and management of the disease. However, in recent years there has been little in the way of therapeutic advancement. At Janssen we are looking to find innovative therapies that will positively impact Type 2 diabetes and DKD patients around the world.Janssen_3c_RGB (1)

We are currently evaluating existing therapies, such as sodium-glucose 2 transporter (SGLT2) inhibitors to help add to the treatment options for DKD through our CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) study. This is the first and only Phase 3 randomized controlled trial assessing the role of an SGLT2 inhibitor in slowing the progression of DKD. Additionally, we also have an earlier stage partnership with Vascular Pharmaceuticals, Inc. to evaluate aVβ3 integrin blockade in DKD.

There is still much more to do for patients with T2DM and DKD. Our team recognizes the significant medical need in combating these disease areas, and it’s this that drives the entire team to harness our expertise with a focus on pursuing novel science and seizing commercial opportunities. We are constantly on the hunt for possible assets or partnership opportunities with companies that are as like-minded as we are in our pursuit of transformational therapies.
Meet leaders from Johnson & Johnson Innovation at BioPharm America taking place in Boston September 15–17, 2015.

Previous Article
AdComm Votes Support the Idea that The FDA is Approving Everything
AdComm Votes Support the Idea that The FDA is Approving Everything

Guest post by Justin Burns, Financial Analyst, BioMedTracker    In August, Forbes’ reporter Matthew Herper ...

Next Article
Addressing Investor Needs as the Life Sciences Ecosystem Expands
Addressing Investor Needs as the Life Sciences Ecosystem Expands

Guest post by Sara Jane Demy, CEO, Demy-Colton Life Science Advisors With the unofficial arrival of Fall co...